Phosphorylation of the C-Raf N Region Promotes Raf Dimerization

REFERENCES

• Bryant KL, Mancias JD, Kimmelman AC, Der CJ. 2014. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 39:91–100. https://doi.org/10.1016/j.tibs.2013.12.004.
   PubMed Web of Science ®Google Scholar
• Fernandez-Medarde A, Santos E. 2011. Ras in cancer and developmental diseases. Genes Cancer 2:344–358. https://doi.org/10.1177/1947601911411084.
   PubMedGoogle Scholar
• McCormick F. 2015. KRAS as a therapeutic target. Clin Cancer Res 21:1797–1801. https://doi.org/10.1158/1078-0432.CCR-14-2662.
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. 2014. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 13:928–942. https://doi.org/10.1038/nrd4281.
   PubMed Web of Science ®Google Scholar
• Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22. https://doi.org/10.1038/nrc969.
   PubMed Web of Science ®Google Scholar
• Baines AT, Xu D, Der CJ. 2011. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 3:1787–1808. https://doi.org/10.4155/fmc.11.121.
   PubMed Web of Science ®Google Scholar
• Mattingly RR. 2013. Activated Ras as a therapeutic target: constraints on directly targeting Ras isoforms and wild-type versus mutated proteins. ISRN Oncol 2013:536529. https://doi.org/10.1155/2013/536529.
   PubMedGoogle Scholar
• Downward J. 2014. RAS's cloak of invincibility slips at last? Cancer Cell 25:5–6. https://doi.org/10.1016/j.ccr.2013.12.016.
   PubMed Web of Science ®Google Scholar
• Stephen AG, Esposito D, Bagni RK, McCormick F. 2014. Dragging ras back in the ring. Cancer Cell 25:272–281. https://doi.org/10.1016/j.ccr.2014.02.017.
   PubMed Web of Science ®Google Scholar
• McCormick F. 2011. Cancer therapy based on oncogene addiction. J Surg Oncol 103:464–467. https://doi.org/10.1002/jso.21749.
   PubMedGoogle Scholar
• Sharma SV, Settleman J. 2007. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214–3231. https://doi.org/10.1101/gad.1609907.
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe AK. 2006. Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457. https://doi.org/10.1038/ncponc0558.
   PubMedGoogle Scholar
• Wellbrock C, Karasarides M, Marais R. 2004. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885. https://doi.org/10.1038/nrm1498.
   PubMed Web of Science ®Google Scholar
• Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, Tzivion G. 2007. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773:1196–1212. https://doi.org/10.1016/j.bbamcr.2007.05.001.
   PubMed Web of Science ®Google Scholar
• Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF, III, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. 2016. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell 29:75–89. https://doi.org/10.1016/j.ccell.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Yoon S, Seger R. 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21–44. https://doi.org/10.1080/02699050500284218.
   PubMed Web of Science ®Google Scholar
• Lavoie H, Therrien M. 2015. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 16:281–298. https://doi.org/10.1038/nrm3979.
   PubMed Web of Science ®Google Scholar
• Weber CK, Slupsky JR, Kalmes HA, Rapp UR. 2001. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61:3595–3598.
   PubMedGoogle Scholar
• Rushworth LK, Hindley AD, O'Neill E, Kolch W. 2006. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26:2262–2272. https://doi.org/10.1128/MCB.26.6.2262-2272.2006.
   PubMed Web of Science ®Google Scholar
• Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. 2009. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542–545. https://doi.org/10.1038/nature08314.
   PubMed Web of Science ®Google Scholar
• Zhang BH, Guan KL. 2000. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19:5429–5439. https://doi.org/10.1093/emboj/19.20.5429.
   PubMed Web of Science ®Google Scholar
• Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJ, Kornev AP, Taylor SS, Shaw AS. 2013. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154:1036–1046. https://doi.org/10.1016/j.cell.2013.07.046.
   PubMedGoogle Scholar
• Lavoie H, Li JJ, Thevakumaran N, Therrien M, Sicheri F. 2014. Dimerization-induced allostery in protein kinase regulation. Trends Biochem Sci 39:475–486. https://doi.org/10.1016/j.tibs.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F, Therrien M. 2013. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 9:428–436. https://doi.org/10.1038/nchembio.1257.
   PubMed Web of Science ®Google Scholar
• Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F, Therrien M. 2015. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol 22:37–43. https://doi.org/10.1038/nsmb.2924.
   PubMed Web of Science ®Google Scholar
• Shaw AS, Kornev AP, Hu J, Ahuja LG, Taylor SS. 2014. Kinases and pseudokinases: lessons from RAF. Mol Cell Biol 34:1538–1546. https://doi.org/10.1128/MCB.00057-14.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, et al.. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949–954. https://doi.org/10.1038/nature00766.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakanian M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabey MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. 2011. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387–390. https://doi.org/10.1038/nature10662.
   PubMed Web of Science ®Google Scholar
• Roring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T. 2012. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 31:2629–2647. https://doi.org/10.1038/emboj.2012.100.
   PubMedGoogle Scholar
• Freeman AK, Ritt DA, Morrison DK. 2013. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 49:751–758. https://doi.org/10.1016/j.molcel.2012.12.018.
   PubMed Web of Science ®Google Scholar
• Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. 2015. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28:370–383. https://doi.org/10.1016/j.ccell.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Brummer T, Shaw PE, Reth M, Misawa Y. 2002. Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO J 21:5611–5622. https://doi.org/10.1093/emboj/cdf588.
   PubMedGoogle Scholar
• Garnett MJ, Rana S, Paterson H, Barford D, Marais R. 2005. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20:963–969. https://doi.org/10.1016/j.molcel.2005.10.022.
   PubMed Web of Science ®Google Scholar
• Morrison DK, Heidecker G, Rapp UR, Copeland TD. 1993. Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 268:17309–17316.
   PubMed Web of Science ®Google Scholar
• Diaz B, Barnard D, Filson A, MacDonald S, King A, Marshall M. 1997. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 17:4509–4516. https://doi.org/10.1128/MCB.17.8.4509.
   PubMed Web of Science ®Google Scholar
• Marais R, Light Y, Paterson HF, Marshall CJ. 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14:3136–3145.
   PubMed Web of Science ®Google Scholar
• Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. 1999. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18:2137–2148. https://doi.org/10.1093/emboj/18.8.2137.
   PubMed Web of Science ®Google Scholar
• Fabian JR, Daar IO, Morrison DK. 1993. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13:7170–7179. https://doi.org/10.1128/MCB.13.11.7170.
   PubMed Web of Science ®Google Scholar
• King AJ, Wireman RS, Hamilton M, Marshall MS. 2001. Phosphorylation site specificity of the Pak-mediated regulation of Raf-1 and cooperativity with Src. FEBS Lett 497:6–14. https://doi.org/10.1016/S0014-5793(01)02425-5.
   PubMedGoogle Scholar
• Barnard D, Diaz B, Clawson D, Marshall M. 1998. Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene 17:1539–1547. https://doi.org/10.1038/sj.onc.1202061.
   PubMedGoogle Scholar
• Williams NG, Roberts TM, Li P. 1992. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc Natl Acad Sci U S A 89:2922–2926. https://doi.org/10.1073/pnas.89.7.2922.
   PubMed Web of Science ®Google Scholar
• Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. 1994. Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463–1467. https://doi.org/10.1126/science.7811320.
   PubMed Web of Science ®Google Scholar
• Stokoe D, McCormick F. 1997. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J 16:2384–2396. https://doi.org/10.1093/emboj/16.9.2384.
   PubMedGoogle Scholar
• Emuss V, Garnett M, Mason C, Marais R. 2005. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65:9719–9726. https://doi.org/10.1158/0008-5472.CAN-05-1683.
   PubMed Web of Science ®Google Scholar
• Tran NH, Wu X, Frost JA. 2005. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 280:16244–16253. https://doi.org/10.1074/jbc.M501185200.
   PubMed Web of Science ®Google Scholar
• Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. 1997. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272:4378–4383. https://doi.org/10.1074/jbc.272.7.4378.
   PubMed Web of Science ®Google Scholar
• Carey KD, Watson RT, Pessin JE, Stork PJ. 2003. The requirement of specific membrane domains for Raf-1 phosphorylation and activation. J Biol Chem 278:3185–3196. https://doi.org/10.1074/jbc.M207014200.
   PubMedGoogle Scholar
• Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. 2014. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer 111:1788–1801. https://doi.org/10.1038/bjc.2014.475.
   PubMedGoogle Scholar
• Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ. 2010. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39:425–435. https://doi.org/10.1097/MPA.0b013e3181c15963.
   PubMed Web of Science ®Google Scholar
• Fabian JR, Vojtek AB, Cooper JA, Morrison DK. 1994. A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. Proc Natl Acad Sci U S A 91:5982–5986. https://doi.org/10.1073/pnas.91.13.5982.
   PubMed Web of Science ®Google Scholar
• Li Y, Takahashi M, Stork PJ. 2013. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation. J Biol Chem 288:27646–27657. https://doi.org/10.1074/jbc.M113.463067.
   PubMedGoogle Scholar
• Lindauer M, Hochhaus A. 2014. Dasatinib. Recent Results Cancer Res 201:27–65. https://doi.org/10.1007/978-3-642-54490-3_2.
   PubMedGoogle Scholar
• Montero JC, Seoane S, Ocana A, Pandiella A. 2011. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17:5546–5552. https://doi.org/10.1158/1078-0432.CCR-10-2616.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. 2004. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658–6661. https://doi.org/10.1021/jm049486a.
   PubMed Web of Science ®Google Scholar
• Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR. 2009. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27:77–83. https://doi.org/10.1038/nbt.1513.
   PubMed Web of Science ®Google Scholar
• Duong HQ, Yi YW, Kang HJ, Bae I, Jang YJ, Kwak SJ, Seong YS. 2014. Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Int J Oncol 44:2132–2138. https://doi.org/10.3892/ijo.2014.2357.
   PubMedGoogle Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132. https://doi.org/10.1038/nbt1358.
   PubMed Web of Science ®Google Scholar
• Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. 1996. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271:695–701. https://doi.org/10.1074/jbc.271.2.695.
   PubMed Web of Science ®Google Scholar
• Ritt DA, Zhou M, Conrads TP, Veenstra TD, Copeland TD, Morrison DK. 2007. CK2 is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr Biol 17:179–184. https://doi.org/10.1016/j.cub.2006.11.061.
   PubMedGoogle Scholar
• Nan X, Collisson EA, Lewis S, Huang J, Tamguney TM, Liphardt JT, McCormick F, Gray JW, Chu S. 2013. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A 110:18519–18524. https://doi.org/10.1073/pnas.1318188110.
   PubMed Web of Science ®Google Scholar
• Nan X, Tamguney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S. 2015. Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. Proc Natl Acad Sci U S A 112:7996–8001. https://doi.org/10.1073/pnas.1509123112.
   PubMed Web of Science ®Google Scholar
• Dementiev A. 2012. K-Ras4B lipoprotein synthesis: biochemical characterization, functional properties, and dimer formation. Protein Expr Purif 84:86–93. https://doi.org/10.1016/j.pep.2012.04.021.
   PubMedGoogle Scholar
• Guldenhaupt J, Rudack T, Bachler P, Mann D, Triola G, Waldmann H, Kotting C, Gerwert K. 2012. N-Ras forms dimers at POPC membranes. Biophys J 103:1585–1593. https://doi.org/10.1016/j.bpj.2012.08.043.
   PubMed Web of Science ®Google Scholar
• Lin WC, Iversen L, Tu HL, Rhodes C, Christensen SM, Iwig JS, Hansen SD, Huang WY, Groves JT. 2014. H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci U S A 111:2996–3001. https://doi.org/10.1073/pnas.1321155111.
   PubMed Web of Science ®Google Scholar
• Spencer-Smith R, Koide A, Zhou Y, Eguchi RR, Sha F, Gajwani P, Santana D, Gupta A, Jacobs M, Herrero-Garcia E, Cobbert J, Lavoie H, Smith M, Rajakulendran T, Dowdell E, Okur MN, Dementieva I, Sicheri F, Therrien M, Hancock JF, Ikura M, Koide S, O'Bryan JP. 2017. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol 13:62–68. https://doi.org/10.1038/nchembio.2231.
   PubMed Web of Science ®Google Scholar
• Baljuls A, Mahr R, Schwarzenau I, Muller T, Polzien L, Hekman M, Rapp UR. 2011. Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. J Biol Chem 286:16491–16503. https://doi.org/10.1074/jbc.M110.194167.
   PubMedGoogle Scholar
• Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867. https://doi.org/10.1016/S0092-8674(04)00215-6.
   PubMed Web of Science ®Google Scholar
• Jambrina PG, Rauch N, Pilkington R, Rybakova K, Nguyen LK, Kholodenko BN, Buchete NV, Kolch W, Rosta E. 2016. Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation. Angew Chem 55:983–986. https://doi.org/10.1002/anie.201509272.
   Google Scholar
• Jambrina PG, Bohuszewicz O, Buchete NV, Kolch W, Rosta E. 2014. Molecular mechanisms of asymmetric RAF dimer activation. Biochem Soc Trans 42:784–790. https://doi.org/10.1042/BST20140025.
   PubMedGoogle Scholar
• Thompson PA, Ledbetter JA, Rapp UR, Bolen JB. 1991. The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T-cells. Cell Growth Differ 2:609–617.
   PubMedGoogle Scholar
• Ishizawar R, Parsons SJ. 2004. c-Src and cooperating partners in human cancer. Cancer Cell 6:209–214. https://doi.org/10.1016/j.ccr.2004.09.001.
   PubMed Web of Science ®Google Scholar
• Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, Buchler MW, Adler G. 1998. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243:503–508. https://doi.org/10.1006/bbrc.1997.8043.
   PubMed Web of Science ®Google Scholar
• Cleghon V, Morrison DK. 1994. Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner. J Biol Chem 269:17749–17755.
   PubMed Web of Science ®Google Scholar
• Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. 2015. Src inhibitors act through different mechanisms in non-small cell lung cancer models depending on EGFR and RAS mutational status. Oncotarget 6:26090–26103. https://doi.org/10.18632/oncotarget.4636.
   PubMedGoogle Scholar
• Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, Lesperance J, Huang M, Schmedt C, Tarin D, Lowy AM, Cheresh DA. 2011. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 30:2123–2134. https://doi.org/10.1038/onc.2010.589.
   PubMedGoogle Scholar
• Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. 2010. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 9:2322–2332. https://doi.org/10.1158/1535-7163.MCT-09-1212.
   PubMed Web of Science ®Google Scholar
• Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG. 2010. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139:292–303. https://doi.org/10.1053/j.gastro.2010.03.034.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. 2004. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10:2307–2318. https://doi.org/10.1158/1078-0432.CCR-1183-3.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Rosen N. 2011. Mutant BRAF melanomas—dependence and resistance. Cancer Cell 19:11–15. https://doi.org/10.1016/j.ccr.2011.01.008.
   PubMed Web of Science ®Google Scholar
• Li Y, Dillon TJ, Takahashi M, Earley KT, Stork PJ. 2016. Protein kinase A-independent Ras protein activation cooperates with Rap1 protein to mediate activation of the extracellular signal-regulated kinases (ERK) by cAMP. J Biol Chem 291:21584–21595. https://doi.org/10.1074/jbc.M116.730978.
   PubMedGoogle Scholar
• Takahashi M, Dillon TJ, Liu C, Kariya Y, Wang Z, Stork PJ. 2013. Protein kinase A-dependent phosphorylation of Rap1 regulates its membrane localization and cell migration. J Biol Chem 288:27712–27723. https://doi.org/10.1074/jbc.M113.466904.
   PubMed Web of Science ®Google Scholar
• Wang Z, Dillon TJ, Pokala V, Mishra S, Labudda K, Hunter B, Stork PJS. 2006. Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 26:2130–2145. https://doi.org/10.1128/MCB.26.6.2130-2145.2006.
   PubMed Web of Science ®Google Scholar
• Liu C, Takahashi M, Li Y, Dillon TJ, Kaech S, Stork PJ. 2010. The interaction of Epac1 and Ran promotes Rap1 activation at the nuclear envelope. Mol Cell Biol 30:3956–3969. https://doi.org/10.1128/MCB.00242-10.
   PubMedGoogle Scholar